As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?
Advertisement
The Scientist
Most Recent
Science adviser John Holdren speaks out about how the Presidential Administration is handling the controversial research that rendered avian flu transmissible between ferrets.
A new policy will require federal agencies to perform a careful review of research involving 15 pathogens and toxins that could be used for bioterrorism, including H5N1.
More than 100 environmental policy organizations call for greater oversight and regulation of synthetic biology.
The FDA considers making some drugs for diabetes, asthma, and other ailments available over the counter.
While biotechnology has met with mixed public reactions, to date nanotechnology seems to invoke much less public concern.
Legislation proposes speeding certain drug applications submitted to the US Food and Drug Administration.
Celebrity spokespeople for pharma companies can manipulate the public’s understanding of disease.
A Swiss-based firm may have a back-door way to thwart a bioterrorist attack—by fighting the flu.
Congress orders the Environmental Protection Agency to review the toxicity ratings of some chemicals and improve its process for making such assessments.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Advertisement
Current Issue
